%PDF-1.4
%
49 0 obj
<>
endobj
46 0 obj
<>
endobj
110 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-08-06T15:31:16Z
2024-03-28T09:07:34-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T09:07:34-07:00
application/pdf
Heather
2003-594.sept
uuid:592b0515-1dd2-11b2-0a00-0609275dc400
uuid:592b0518-1dd2-11b2-0a00-810000000000
endstream
endobj
35 0 obj
<>
endobj
36 0 obj
<>
endobj
50 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 21 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 23 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 25 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 27 0 R/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 29 0 R/Type/Page>>
endobj
128 0 obj
[132 0 R]
endobj
129 0 obj
<>stream
q
0 0 612 783 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6283 0.7779 -0.7779 0.6283 8.2321 49.765 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 783 m
0 783 l
f
q
-1 784 587 -785 re
W n
q
0 783.03 612 -783 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.0051 Tc 0.1441 Tw 10 0 0 10 43 731.1616 Tm
[(observed in our Italian population. )17.6 (W)79.9 (e investigated )17.6 (VEGF)]TJ
0.2386 Tw 0 -1.2 TD
(polymorphism associations with BD stratifying on HLA-)Tj
0.0388 Tw T*
[(B51. )17.7 (The association of BD with I and C634 alleles seemed)]TJ
-0.0106 Tw T*
[(to be dependent on the status of HLA-B51 allele. )17.6 (The I allele)]TJ
0.2153 Tw T*
(was significantly associated with BD only in HLA-B51+)Tj
-0.0103 Tw T*
[(patients, and \320634C only in HLA-B51\320 patients. )17.6 (This should)]TJ
0.09109 Tw T*
[(be interpreted with caution, however)39.6 (, since the sample size)]TJ
0.02499 Tw T*
(of HLA-B51 +/\320 patients after stratification was small.)Tj
-0.0101 Tc 0.0302 Tw 1.2 -1.2 Td
[(W)79.9 (e)-0.1 ( found no dif)17.8 (ference in the frequencies of )17.8 (VEGF poly-)]TJ
0.22771 Tw -1.2 -1.2 Td
(morphisms in patients with BD with and without clinical)Tj
0.145 Tw T*
[(manifestations, except for +936T)-367.2 (allele, which was signifi-)]TJ
0.2906 Tw T*
(cantly more frequent in patients with BD with posterior)Tj
0.0141 Tw T*
[(uveitis/retinal vasculitis than in those without. )18 (The functional)]TJ
0.32359 Tw T*
(relevance of this association is unclear because subjects)Tj
-0.0127 Tw T*
[(carrying this mutation have significantly lower )17.9 (VEGF plasma)]TJ
0.02499 Tw T*
(levels than subjects carrying the +936 CC genotype)Tj
0 Tw 6.5 0 0 6.5 246.1664 554.4615 Tm
(17)Tj
0 Tc 10 0 0 10 252.5364 551.1616 Tm
(.)Tj
-0.00011 Tc 0.0757 Tw -19.7536 -1.2 Td
(Our data indicate that carriers of \320634C and allele I are)Tj
0.1859 Tw -1.2 -1.2 Td
[(associated with susceptibility to developing BD. )17.7 (These 2)]TJ
0.0079 Tc 0.367 Tw T*
[(polymorphisms may be associated with higher )17.8 (VEGF)]TJ
-0.00011 Tc 0.0125 Tw T*
[(production. However)39.7 (, due to the limited power of the study)64.8 (,)]TJ
0.03729 Tw T*
(multicenter collaborations to recruit an adequate number of)Tj
0.02499 Tw T*
(patients are required in order to confirm our data.)Tj
/T1_2 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES )Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 50 445.1616 Tm
[(1.)-875.1 (Sakane )17.7 (T)74 (,)-0.1 ( )17.7 (T)69.9 (akeno M, Suzuki N, Inaba G. Beh\215et\325)54.8 (s disease. N Engl)]TJ
0 Tc 1.675 -1.25 Td
(J Med 1999;341:1284-91.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(2.)-875.1 (Y)99.8 (azici H, )36.8 (Y)110.8 (urdakul S, Hamuryudan )17.7 (V)128.9 (. Beh\215et\325)54.8 (s syndrome. Curr)]TJ
1.675 -1.25 Td
(Opin Rheumatol 2001;13:18-22.)Tj
-1.675 -1.25 Td
[(3.)-875.1 (Kansu E, Sahin G, Sahin F)79.7 (, Sivri B, Sayek I, Batman F)79.7 (. Impaired)]TJ
1.675 -1.25 Td
[(prostacyclin synthesis by vessel walls in Beh\215et\325)54.8 (s disease [letter].)]TJ
0 -1.25 TD
[(Lancet 1986;2:1)36.8 (154.)]TJ
-1.675 -1.25 Td
[(4.)-875.1 (Hizli N, Sahin G, Sahin F)79.7 (, Sivri B, Sayec I, Batman F)79.7 (. Plasma)]TJ
1.675 -1.25 Td
[(prostacyclin levels in Beh\215et\325)54.8 (s disease [letter]. Lancet 1985;1:1454.)]TJ
-1.675 -1.25 Td
[(5.)-875.1 (Haznedaroglu IC, Ozcebe OI, Ozdemir O, Celik I, Dundar SV)128.8 (,)]TJ
1.675 -1.25 Td
(Kirazli S. Impaired haemostatic kinetics and endothelial function in)Tj
T*
[(Beh\215et\325)54.8 (s disease. J Intern Med 1996;240:181-7.)]TJ
-1.675 -1.25 Td
[(6.)-875.1 (Y)99.8 (azici H, Hekim N, Ozbakir F)79.7 (, et al. )17.7 (V)128.9 (on )17.7 (W)39.8 (illebrand factor in)]TJ
1.675 -1.25 Td
[(Beh\215et\325)54.8 (s syndrome. J Rheumatol 1987;14:305-6.)]TJ
-1.675 -1.25 Td
[(7.)-875.1 (Hizli N, Sahin G, Sahin F)79.7 (, et al. Plasma von )17.7 (W)39.8 (illebrand factor)39.7 (,)]TJ
1.675 -1.25 Td
[(tissue plasminogen activator)39.7 (, plasminogen activator inhibitor)39.7 (, and)]TJ
T*
[(antithrombin III levels in Beh\215et\325)54.8 (s disease. Scand J Rheumatol)]TJ
0 Tc 0 Tw T*
(1995;24:376-82.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(8.)-875.1 (Direskeneli H, Keser G, D\325Cruz D, et al. )54.8 (Anti-endothelial )]TJ
1.675 -1.25 Td
[(cell antibodies, endothelial proliferation and von )17.7 (W)39.9 (illebrand factor)]TJ
T*
[(antigen in Beh\215et\325)54.8 (s disease. Clin Rheumatol 1995;14:55-61.)]TJ
-1.675 -1.25 Td
[(9.)-875.1 (Boehme MW)91.7 (, Schmitt )17.7 (WH, )36.8 (Y)99.8 (ouinou P)110.7 (, Stremmel )17.7 (WR, Gross )17.7 (WL.)]TJ
1.675 -1.25 Td
(Clinical relevance of elevated serum thrombomodulin and soluble)Tj
T*
[(E-selectin in patients with )17.7 (W)79.9 (egener)-37 (\325)55.1 (s granulomatosis and other)]TJ
T*
[(systemic vasculitides. )54.8 (Am J Med 1996;10:387-94.)]TJ
-2.175 -1.25 Td
[(10.)-875.1 (Ohdama S, )17.7 (T)69.9 (akano S, Miyake S, Kubota )17.7 (T)74 (, Sato K, )54.8 (Aoki N. Plasma)]TJ
2.175 -1.25 Td
(thrombomodulin as a marker of vascular injuries in collagen)Tj
T*
[(vascular diseases. )54.8 (Am J Clin Pathol 1994;101:109-13.)]TJ
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Chambers JC, Haskard DO, Kooner JS. )17.7 (V)110.8 (ascular endothelial )]TJ
2.1381 -1.25 Td
[(function and oxidative stress mechanisms in patients with Behcet\325)54.8 (s)]TJ
T*
[(syndrome. J )54.8 (Am Coll Cardiol 2001;37:517-20.)]TJ
0.00729 Tw -2.175 -1.25 Td
[(12.)-875.1 (Marumo T)74 (, )-17.7 (Schini-Kerth VB, )-17.8 (Busse )-17.8 (R. V)110.8 (ascular )-17.7 (endothelial )-17.7 (growth)]TJ
0.02499 Tw 2.175 -1.25 Td
[(factor activates nuclear factor)19.7 (-kappa B and induces monocyte)]TJ
T*
(chemoattractant protein-1 in bovine retinal endothelial cells.)Tj
T*
[(Diabetes 1999;48:1)36.8 (131-7.)]TJ
30.825 78.421 Td
[(13.)-875.1 (Kim I, Moon SO, Kim SH, Kim HJ, Koh )36.8 (YS, Koh GY)128.8 (. )17.7 (V)110.8 (ascular)]TJ
2.175 -1.25 Td
(endothelial growth factor expression of intercellular adhesion )Tj
T*
(molecule 1 \(ICAM-1\), vascular cell adhesion molecule 1 )Tj
T*
[(\(VCAM-1\), and E-selectin through nuclear factor)19.7 (-kappa B )]TJ
T*
(activation in endothelial cells. J Biol Chem 2001;276:7614-20.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (T)35 (ugal-T)34.8 (utkun I, Ur)17.7 (gancioglu M, Foster CS. Immunopathologic)]TJ
2.175 -1.25 Td
[(study of the conjunctiva in patients with Beh\215et\325)54.8 (s disease.)]TJ
0 Tc T*
(Ophthalmology 1995;102:1660-8.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(15.)-875.1 (Gul )54.8 (A, Esin S, Dilsen N, Konice M, )17.7 (W)39.9 (igzell H, Biberfeld P)110.7 (.)]TJ
2.175 -1.25 Td
[(Immunohistology of skin pather)17.7 (gy reaction in Behcet\325)54.8 (s disease. Br)]TJ
T*
(J Dermatol 1995;132:901-7.)Tj
-2.175 -1.25 Td
[(16.)-875.1 (W)79.9 (atson CJ, )17.7 (W)79.9 (ebb NJA, Bottomley MJ, Brenchley PEC. Peripheral)]TJ
2.175 -1.25 Td
[(mononuclear cells express )17.7 (VEGF and the )17.7 (VEGF receptor flt-1)]TJ
T*
[([abstract]. J )54.8 (Am Soc Nephrol 1996;7:A2390.)]TJ
-2.175 -1.25 Td
[(17.)-875.1 (Renner )17.7 (W)91.8 (, Kotschan S, Hof)17.7 (fmann C, Obermayer)19.7 (-Pietsch B, Pilger)]TJ
2.175 -1.25 Td
[(E. )54.8 (A)-220.1 (common 936 C/T)-257.3 (mutation in the gene for vascular endothelial)]TJ
T*
(growth factor is associated with vascular endothelial growth factor)Tj
T*
[(plasma levels. J )17.7 (V)110.8 (asc Res 2000;37:443-8.)]TJ
-2.175 -1.25 Td
[(18.)-875.1 (W)79.9 (atson CJ, )17.7 (W)79.9 (ebb NJ, Bottomley MJ, Brenchley PE. Identification)]TJ
2.175 -1.25 Td
(of polymorphisms within the vascular endothelial growth factor)Tj
T*
[(\(VEGF\) gene: correlation with variation in )17.7 (VEGF protein )]TJ
T*
(production. Cytokine 2000;12:1232-5.)Tj
-2.175 -1.25 Td
[(19.)-875.1 (Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica )17.7 (V)128.9 (, Hutchinson)]TJ
2.175 -1.25 Td
[(IV)128.8 (. Novel polymorphisms in the promoter and 5\325)-201.1 (UTR regions of)]TJ
T*
(the human vascular endothelial growth factor gene. Hum Immunol)Tj
0 Tc 0 Tw T*
(1999;60:1245-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(20.)-875.1 (Criteria for diagnosis of Beh\215et\325)54.8 (s disease. International Study)]TJ
2.175 -1.25 Td
[(Group for Beh\215et\325)54.8 (s disease. Lancet 1990;335:1078-80.)]TJ
-2.175 -1.25 Td
[(21.)-875.1 (T)69.9 (erasaki PI, McClelland JD. Microdroplet assay for human serum)]TJ
2.175 -1.25 Td
(cytotoxins. Nature 1964;204:998-1000.)Tj
-2.175 -1.25 Td
[(22.)-875.1 (Boiardi L, Casali B, Nicoli D, et al. )17.7 (V)110.8 (ascular endothelial growth)]TJ
2.175 -1.25 Td
(factor gene polymorphisms in giant cell arteritis. J Rheumatol)Tj
0 Tc 0 Tw T*
(2003;30:2160-4.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(23.)-875.1 (Salvarani C, Boiardi L, Mantovani )17.7 (V)128.9 (, et al. )54.8 (Association of MICA)]TJ
2.175 -1.25 Td
[(alleles and HLA-B51 in Italian patients with Beh\215et\325)54.8 (s disease. )]TJ
T*
(J Rheumatol 2001;28:1867-70. )Tj
-2.175 -1.25 Td
[(24.)-875.1 (V)110.8 (erity DH, )17.7 (V)110.8 (aughan R)54.8 (W)91.9 (, Kondeatis E, et al. Intercellular adhesion)]TJ
2.175 -1.25 Td
[(molecule-1 gene polymorphisms in Behcet\325)54.8 (s disease. Eur )]TJ
T*
(J Immunogenet 2000;27:73-6.)Tj
-2.175 -1.25 Td
[(25.)-875.1 (Boiardi L, Salvarani C, Casali B, et al. Intercellular adhesion )]TJ
2.175 -1.25 Td
[(molecule-1 gene polymorphisms in Behcet\325)54.8 (s disease. J Rheumatol)]TJ
0 Tc 0 Tw T*
(2001;28:1283-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(26.)-875.1 (Salvarani C, Boiardi L, Casali B, et al. Endothelial nitric oxide)]TJ
2.175 -1.25 Td
[(synthase gene polymorphisms in Behcet\325)54.8 (s disease. J Rheumatol)]TJ
0 Tc 0 Tw T*
(2002;29:535-40.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(27.)-875.1 (Kobayashi M, Ito M, Nakagawa )54.8 (A, et al. Neutrophil and endothelial)]TJ
2.175 -1.25 Td
(cell activation in the vasa vasorum in vasculo-Beh\215et disease.)Tj
T*
(Histopathology 2000;36:362-71.)Tj
-2.175 -1.25 Td
[(28.)-875.1 (Cid MC. New developments in the pathogenesis of systemic)]TJ
2.175 -1.25 Td
[(vasculitis. Curr Opin Rheumatol 1996;8:1-1)36.8 (1.)]TJ
-2.175 -1.25 Td
[(29.)-875.1 (Cid MC, Cebrian M, Font C, et al. Cell adhesion molecules in the)]TJ
2.175 -1.25 Td
(development of inflammatory infiltrates in giant cell arteritis:)Tj
T*
(inflammation-induced angiogenesis as the preferential site of )Tj
T*
[(leukocyte-endothelial cell interactions. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2000;43:184-94.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(30.)-875.1 (A)91.8 (wata )17.7 (T)74 (, Inoue K, Kurihara S, et al. )54.8 (A)-220.1 (common polymorphism in)]TJ
2.175 -1.25 Td
[(the 5\325-untranslated region of the )17.7 (VEGF gene is associated with)]TJ
T*
(diabetic retinopathy in type 2 diabetes. Diabetes 2002;51:1635-9.)Tj
-2.175 -1.25 Td
[(31.)-875.1 (Y)110.8 (uuki )17.7 (T)74 (, Kanda )17.7 (T)74 (, Kimura )36.8 (Y)128.9 (, et al. Inflammatory cytokines in)]TJ
2.175 -1.25 Td
[(vitreous fluid and serum of patients with diabetic vitreoretinopathy)64.8 (.)]TJ
T*
(J Diabetes Complications 2001;15:257-9.)Tj
-2.175 -1.25 Td
[(32.)-875.1 (Shahbazi M, Fryer )54.8 (AA, Pravica )17.7 (V)128.9 (, et al. )17.7 (V)110.8 (ascular endothelial)]TJ
2.175 -1.25 Td
(growth factor gene polymorphisms are associated with acute renal)Tj
T*
[(allograft rejection. J )54.8 (Am Soc Nephrol 2002;13:260-4.)]TJ
ET
0 0 0 1 K
43 72 m
547 72 l
S
BT
/T1_3 1 Tf
8 0 0 8 43.5 53.9844 Tm
(Salvarani, et al: VEGF polymorphisms in BD)Tj
0 Tc 0 Tw 60.9375 -0.0313 Td
(1789)Tj
ET
0 0 0 0 k
/GS0 gs
96.22 76.74 396.48 -10.83 re
f*
0.5 w
96.22 76.74 396.48 -10.83 re
S
Q
Q
q
0 0 612 783 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
110.368 69 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 8 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
29 0 obj
<>stream
8;Z\6!HR6T#ikq,j?(t:/KnS>a541IF&R:OVMPCG#dF3pqQ%eM\Qn[gA&mcYf2L"B
5%"7Z>g6i#btVQsf7,C!KrrY-j(gsYqJ0^D)6LYECA'\u*QBie"4/%eaB"Aq(rlb&
n.@8i)djXo"iSDBmd#\tj>"Dq';J]s7N5a*!o3B/=bs-c.X2'q#N#AfI6T4VuLrPloL_E5JAI!d;]@MNoq0bT\lN(c"t[8DdHdkE;X%Eh;d@"Xr/JH9oRCN
F10VuLNQ9NJ_"M8NE2#"#`P"+SU)!P0a@<%G<+,C$GGp)>]OGEqgE#ILAiJtd_)=?
:0d286LjqVNHCU',Y`d3>-P/VT((<%VbrL+S62!>3%;uW;\tdUZnO9#6NDJqogF$+
U*`"k84.FPK*G)Ya-jfEni#IU1W^P9495s=B,iS"phrN0>TE+3h4k=6'72J=CiRGq
=jE&;mE.%4iO4\[TiP%fr6Q,Z,mmQN,f$nn2^<[siL#F<5"qDaOH.U/^7[0uHmX?7
:"GH,TQ6#^i5X1W/XC9A:N`sXN4kTiABDdq=^!E8;&T%X5M,@,6e]NU@ntIP2BL8!
1nCH*_D*g3;b+ki(fO_]U$1uj20!Em9)J3RA92Zj0b'Z9mO)lcog9T-gbO4S9[:es
WAU7WCe:MeA)p*Ug9@M08L,eGh&;*8Ri4.@GhJ$6?oUG55,C-=g=[17DNO[+;u:GnJq=(`l8P@WWUIA5FQ!%`O
%i=XoUkGS1];"KsWk\1qI;d%V.3*P(e94D!bYc/44ID0j3MQ*&>@+D(KbHfe7_%32
H4Z:?HHn08n6rYQKmjU^'3f:C&g
endstream
endobj
33 0 obj
[/Indexed/DeviceRGB 255 32 0 R]
endobj
32 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
99 0 obj
<>
endobj
59 0 obj
<>
endobj
13 0 obj
<>
endobj
52 0 obj
<>
endobj
88 0 obj
<>
endobj
115 0 obj
<>
endobj
53 0 obj
<>
endobj
80 0 obj
<>stream
HUiPTW~k-C62"h
&, Ahf醦YnZ6Yh[YPL\#*!c&f2Td\fi5&NWι]35p
(4xmŧ`1gV0u>&d%qҔqG[/fkhig]V_q/^^>;,^R975M퉂.gX(ÂAVlOKrBnV1fbOȉ爲T'.3
,'NyY<jߜK>[jY/ޱvPXm`n`0#X=Ɲl1b&~ğLMUߐYX#f0PN|ז%a|iۊ;_Viejkmg]akdvVv_сt}O:8;8wZwr)+.;ԅ3q~62_&.,IINj|a@A(Zg"
eC&)^.h.K Wv31i%"LѲo\WzJǗS}瞀8zuc /ŧuK>Iy/ΌN
˖#yuꞷ<Ů{-
gN=(J'+sTz~Y4l}I+p5|:ɗ)ғD e6 q43&IZPF9vf(:)^DVR^_? UF!G
!6إz3'. {'/ώ5i
(9v !ME2
QBdܾ
SH7-JPڐYڗ8=im~[e~-F9[ЊF9v3(YMcgp!٥;39-fl3ؖgFIԭI6
ųw.7J$^Hlw65h`Q Rf?]\T֔){!ĎA+&O6hxVru/4T:UX5G kgov"dAug.PZx_yU%}Сch%8[ \ئtS\)dR|s[ eѝϾݤTF"rLH.O-SKk:)6h;yq⌵`l>?12A(шV5=?YmhyP/